Business
Uptick Newswire Hosts Premier Biomedical, Inc. on The Stock Day Podcast to Discuss the Company’s Current Projects
Uptick Newswire Hosts Premier Biomedical, Inc. on The Stock Day Podcast to Discuss the Company’s Current Projects.
About this update from Premier Biomedical Inc
[{"type":"text","content":"\nPHOENIX, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast welcomed Premier Biomedical, Inc. (BIEI), a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. President and CEO, William A. Hartman, joined Stock Day host Everett Jolly.\n Jolly began the interview by asking Hartman to give an update to listeners about the Company’s current projects. Hartman explained the Company was previously strictly a R&D based business. This went well for the Company, they were forced to put their very successful projects, including a cure for PTSD as well as an anti-breast cancer drug on the shelf and morph the company into developing and marketing a revenue-producing series of hemp oil/CBD topical pain-relieving products. To explain the Company’s current position, Hartman shared a letter with listeners that the company sent out recently to 29 of its Directors, Officers, and sales force. Hartman also stated that the letter would soon be sent out to the company’s stockholders and its e-mail distribution list. The letter stated: “We currently have eight topical, all-natural, 50-state- legal, pesticide- and solvent-free, hemp oil/CBD, topical pain relief products that, we believe, are the very best on the market.” Hartman shared that the products developed by the Company are created with a proprietary formula, which makes them more effective than competitors and at a lower price. “Unsolicited testimonies from satisfied customers validate our claims,” added Hartman. Hartman also explained that the Company has sold most of their products online to date, with some smaller percentage of sales to pharmacies and medical facilities. However, the Company received a serious blow to its online sales when Amazon refused to list any products on their platform with CBD listed as an ingredient. Hartman is optimistic that the passing of the 2018 Farm Bill will eventually shift Amazon’s stance on the subject, but it may take some time. In the interim, the Company will be reestablishing their position on Amazon by creating a product line labeled, “Nature’s Own Pain Relief”. This product line will not have CBD listed on the label and will therefore comply with Amazon’s guidelines. The Compan...